Pomegranate proves potent in metabolic health management
A comprehensive study featured in Nutrients journal has cast a spotlight on pomegranate (Punica granatum l., PG) and its polyphenolic compounds, scrutinising their potential to modulate metabolic irregularities. Historically embraced for its therapeutic properties against bacterial infections, diabetes, and various metabolic syndromes, pomegranate’s efficacy is being re-evaluated amidst concerns over the side effects of conventional pharmacological treatments.
The review delves into pomegranate’s pharmacokinetic profiles, safety, and bioavailability, particularly focusing on its capacity to combat metabolic disorders such as type 2 diabetes, obesity, dyslipidemia, and cardiovascular diseases. It outlines how PG’s consumption could attenuate insulin resistance, inflammatory cytokines, redox gene expression, blood pressure elevation, vascular damage, and lipoprotein oxidation.
In animal models, pomegranate seed oil has been found to reduce fat mass and enhance insulin sensitivity, corroborating previous research indicating significant reductions in lipid levels. The study further explains how enzymes and nuclear receptors involved in lipid metabolism are positively influenced by PG’s floral components.
Despite some contradictory findings regarding PG’s impact on food intake and weight gain, the review suggests genetic differences may account for varied physiological reactions to phytochemicals. PG polyphenols are also being explored for their anti-diabetic properties through diverse mechanisms, including modulation of PPAR-γ activity and adiponectin gene expression.
The review also evaluates the pharmacodynamics and safety of PG’s ellagitannin compounds, noting individual differences in urolithin production and absorption, which are influenced by factors such as gut microbiota composition and pH. Although high doses of PG have shown cellular and nuclear alterations in toxicological studies, conventional uses of PG and its compounds appear safe, with adverse effects only predicted at dosages exceeding those traditionally used in ethnomedicine.
In conclusion, the research indicates that PG could play a beneficial role in preventing metabolic disorders. However, the outcomes of clinical and pharmacokinetic studies remain variable, attributed to factors like plant part selection, cultivar differences, environmental conditions, bioavailability, organ accessibility, and individual genetic profiles. Despite these discrepancies, the therapeutic potential of PG in addressing components of metabolic syndrome highlights the need for integrated treatment strategies.
